MedTrace Logo

Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation

NCT01243008 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2010-11-19

No results posted yet for this study

Summary

IXODES GmbH intends to develop SHB001, an azithromycin dermal formulation in order to prevent Lyme disease at early stages of infection after tick bite.

Conditions

  • Lyme Disease

Interventions

DRUG

Application of SHB001

* Cohort 1: Application of SHB001 on the skin of right thigh * Cohort 2: 1. Application of SHB001 on the skin of right thigh 2. punch biopsies of treated skin areas

Sponsors & Collaborators

  • Ixodes GmbH

    collaborator UNKNOWN

  • Appletree AG

    collaborator INDUSTRY

  • University of Zurich

    lead OTHER

Principal Investigators

  • 01 Studienregister MasterAdmins · UniversitaetsSpital Zuerich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01243008 on ClinicalTrials.gov